| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Brief Communications |
1 Division of Nuclear Medicine, University Hospital of Lausanne, Lausanne, Switzerland
2 Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Bern, Bern, Switzerland
3 Center for Radiopharmaceutical Science, Paul Scherrer Institute, Villigen, Switzerland
4 Department of Organic Chemistry, Vrije University Brussels, Brussels, Belgium
ABSTRACT
The study aim was to assess the safety, biodistribution, tissue kinetics, and tumor uptake of the 99mTc-labeled neurotensin (NT) analog NT-XI. Methods: Four patients presenting ductal pancreatic adenocarcinoma were studied with 99mTc-NT-XI. Patients were followed by scintigraphy up to 4 h and by continued blood and urinary sampling until surgery 18–22 h after injection. Surgical tissue samples were analyzed for radioactivity uptake and NT receptor expression. Results: No side effects were observed on injection of 99mTc-NT-XI. Blood biologic half-lives 
and ß were 35 min (range, 17–62 min) and 230 min (range, 107–383 min), respectively. Repeated whole-body scintigraphy performed in 2 patients showed a single exponential decrease of whole-body activity with half-lives of 101 and 232 min. Tracer elimination was mainly renal, with 92% and 98% of activity counted in urine in the first 20 h. Kidney, liver, spleen, and bone marrow activity uptake was observed in all patients. Tumor was not visualized in the first 3 patients but could be localized by tomoscintigraphy in the pancreas head region of patient 4. In vitro tissue analysis showed high expression of NT receptor in the tumor of patient 4, correlated with the highest tumor radioactivity uptake and the highest tumor-to-fat radioactivity ratio. In vitro receptor expression was also positive in a second patient having a tumor characterized by very low cellularity; however, the remaining 2 tumors lacked NT receptor expression. Conclusion: Injection of 99mTc-NT-XI was well tolerated. The in vivo tumor uptake appeared specific as it was observed in the 1 patient with a pancreatic tumor that expressed high amounts of NT receptor. The results are compatible with preclinical animal results and in favor of further development of radiolabeled NT analogs for diagnosis or therapy of cancer.
Key Words: neurotensin scintigraphy • ductal pancreatic adenocarcinoma
This article has been cited by other articles:
|
|
 |
|
  C. Falciani, M. Fabbrini, A. Pini, L. Lozzi, B. Lelli, S. Pileri, J. Brunetti, S. Bindi, S. Scali, and L. Bracci Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting Mol. Cancer Ther., September 1, 2007; 6(9): 2441 - 2448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lipowska, H. He, E. Malveaux, X. Xu, L. G. Marzilli, and A. Taylor First Evaluation of a 99mTc-Tricarbonyl Complex, 99mTc(CO)3(LAN), as a New Renal Radiopharmaceutical in Humans J. Nucl. Med., June 1, 2006; 47(6): 1032 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Korner, G. M. Hayes, R. Rehmann, A. Zimmermann, H. Friess, L. J. Miller, and J. C. Reubi Secretin Receptors in Normal and Diseased Human Pancreas: Marked Reduction of Receptor Binding in Ductal Neoplasia Am. J. Pathol., October 1, 2005; 167(4): 959 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Reubi, H. R. Macke, and E. P. Krenning Candidates for Peptide Receptor Radiotherapy Today and in the Future J. Nucl. Med., January 1, 2005; 46(1_suppl): 67S - 75S. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
